Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, the adenocarcinomas were positive for CK7 (4/4), CEA (4/4), MUC6 (3/3), PAX8 (3/4), CK20 (2/4), CDX2 (2/4), and estrogen receptor (1/4).
|
31567280 |
2020 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Biopsy findings revealed a moderately differentiated adenocarcinoma with immunohistochemical profile supporting prostate as the primary tumor site: negative for cytokeratin-7 and cytokeratin-20 and positive for prostate-specific antigen, prostate-specific acid phosphatase, and alpha-methylacyl-CoA-racemase.
|
30832497 |
2020 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The tumor cells were positive for CDX-2 and cytokeratin 20 and negative for cytokeratin 7 and thyroid transcription factor-1, consistent with an enteric/colonic-type adenocarcinoma, demonstrating progressive atypia and malignancy.
|
31520753 |
2019 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
After 12 mo of treatment with icotinib, ovarian biopsy showed adenocarcinoma with CDX2(-), TTF-1(+++), PAX8(-), CK-7(+++), CK-20(++), and Ki67(15%+), accompanied with EGFR 19-del mutation and T790M mutation.
|
31363481 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, immunohistochemical staining of the tissue specimen for thyroid transcription factor 1, cytokeratin 7 (CK7), and CK20 and CT-guided gun biopsy of the lung mass confirmed the presence of an adenocarcinoma that originated from the lung.
|
30653118 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, the adenocarcinomas were positive for MUC6 (4/5), PAX8 (3/5), CK7 (5/5), CK20 (1/5), CDX2 (5/5), CA19.9 (5/5), CEA (4/5), CA125 (5/5), and hepatocyte nuclear factor 1β (5/5). p16, estrogen receptor, and Napsin A were negative in all cases tested, whereas p53 exhibited mutation-type staining in 3/5 cases.
|
29664741 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The aim of this study was to explore a new intestinal marker, SATB2, in conjunction with CDX2 and CK20 in differential diagnosis of sinonasal adenocarcinomas.
|
27258560 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Factors related with shorter overall survival was adenocarcinoma histology (<i>P</i>=0.001), increased CA19-9 (<i>P</i>=0.003), increased CEA (<i>P</i>=0.047), increased LDH (<i>P</i><0.001), CK20 positivity (<i>P</i>=0.002), presence of bone metastasis (<i>P</i>=0.017), metastasis not confined to the lymph nodes (<i>P=</i>0.015), unfavorable clinical group based predefined category (<i>P</i>=0.017), and patients with no treatment (<i>P</i><0.001).
|
28977975 |
2017 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Histopathological and immunohistochemical examination revealed a well-differentiated adenocarcinoma (strongly positive staining for cytokeratin 20 and CDX2), pT3N0 stage IIA.
|
29556659 |
2017 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
A panel consisting of cytokeratin (CK) 7, CD20, and CDX2 antibodies is typically used to diagnose gastrointestinal adenocarcinomas.
|
28029907 |
2017 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Twenty-five previously reported cases, classified as mucinous adenocarcinoma and adenocarcinoma, not otherwise specified, also had similar characteristics to enteric-type adenocarcinoma and generally expressed CK20, CDX2, CEA, and/or MUC2.Some of these cases had a thymic cyst.
|
28038793 |
2017 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Comparison of spheroids with the original tumour revealed that spheroid culture generally preserved adenocarcinoma histology and expression patterns of cytokeratin 20 and carcinoembryonic antigen.
|
28877221 |
2017 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The adenocarcinoma showed strong immunohistochemical expression of CK20 and p53, but CK7 in patches.
|
25039399 |
2015 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
As was expected, CK7 expression was documented in all 9 PEACs and 20 tPCAs while CK20 was significantly more prevalent in adenocarcinoma that originated from colorectal.
|
24696747 |
2014 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Regarding MSI, in case with no BRAF mutations, a progressive decrease in CK20 expression was noted, and in BRAF-mutated adenocarcinomas, no expression of CK20 was observed.
|
22361037 |
2012 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Metastatic colorectal adenocarcinomas were positive for CK20 (100%), CDX-2 (100%), and PDX-1 (33%), whereas were negative for CA-125 and CK7.
|
18665037 |
2008 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The pattern of coordinated expression of cytokeratin (CK) 7 and CK20 is also useful for the diagnosis of the origin of metastatic adenocarcinomas.
|
15894926 |
2005 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Thirteen of 212 adenocarcinomas expressed CK20; 29 expressed CDX2; K-ras mutation was identified in 28; and goblet cell features were present in 19.
|
15141379 |
2004 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, the adenocarcinoma strongly stained for cytokeratin 20 and carcinoembryonic antigen, while the endocrine component displayed a dot-like positivity for pan-cytokeratins and chromogranin.
|
15316325 |
2004 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Diverse proteomic alterations in gastric adenocarcinoma.
|
15378696 |
2004 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Therefore, we evaluated the combined immunohistochemical expression of CK7 and CK20 on paraffin-embedded material of 214 resection specimens for adenocarcinoma, comprising 66 esophageal, 73 cardiac and 75 distal gastric adenocarcinomas (UICC-classification).
|
14631371 |
2004 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
This report directly compares CK20 mRNA and protein expression in serial sections of archival, formalin-fixed, paraffin-embedded (FFPE) colorectal adenocarcinomas.
|
12237879 |
2002 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In gastrointestinal carcinomas similarly examined, CK 20 has been detected in almost all cases (50/52) of colorectal adenocarcinomas, including all grades of differentiation and malignancy and also metastatic tumors, whereas CK 20 immunostaining in gastric carcinomas has been found less consistent and more heterogeneous.
|
8359595 |
1993 |